Diasome Pharmaceuticals

About:

Diasome Pharmaceuticals is a clinical-stage diabetes therapeutics company that designs and develops insulin-based therapies.

Website: https://www.diasome.com/

Twitter/X: diasome

Top Investors: Medicxi, JDRF T1D Fund, Quaker BioVentures, McDonald Partners, Devon Park BioVentures

Description:

Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products for patients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania.

Total Funding Amount:

$92M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cleveland, Ohio, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)diasome.com

Founders:

Robert Geho, W. Blair Geho

Number of Employees:

1-10

Last Funding Date:

2023-06-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai